A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
Providing Medicaid coverage is likely to lead to meaningful health benefits for at least a subset of previously uninsured, low-income Americans, according to a post-hoc analysis of the randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results